Organon
About Organon
Organon is a company based in Jersey City (United States) was acquired by Sun Pharma in April 2026. It operates as a Direct-to-Consumer (D2C) and Professional Services. Organon has completed 4 acquisitions, including Alydia Health, Dermavant and Forendo Pharma. Organon offers products and services including Women's Health Solutions, Biosimilars, and Established Brands. Organon operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter Jersey City, United States
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Organon & Co.
-
Annual Revenue
$6.4 B (USD)2.24as on Dec 31, 2024
-
Net Profit
$864 M (USD)-15.54as on Dec 31, 2024
-
EBITDA
$1.77 B (USD)13.56as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Merck
& 1 more
-
Employee Count
Not available
-
Investments & Acquisitions
Alydia Health
& 3 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Organon
Organon is a publicly listed company on the NYSE with ticker symbol OGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Organon
Organon offers a comprehensive portfolio of products and services, including Women's Health Solutions, Biosimilars, and Established Brands.
Solutions for women's reproductive and maternal health are provided.
Accessible treatment options through biosimilars are made available.
Therapies for various conditions like cardiovascular are offered.
People of Organon
Unlock access to complete
Unlock access to complete
Leadership Team
88 people
Software Development Team
55 people
Finance and Accounting
29 people
Data Analysis and Operations Team
22 people
Legal and Compliance
19 people
Operations Team
17 people
Product Management Team
15 people
Human Resources and Administration
14 people
Unlock access to complete
Funding Insights of Organon
Detailed funding history for Organon
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Organon
Organon has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Merck and Sun Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical products are manufactured and marketed worldwide.
|
Locked | Locked | Locked | |
|
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
|
Locked | Locked | Locked |
Investor details for Organon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Organon
Organon has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Alydia Health, Dermavant and Forendo Pharma.
Investment portfolio details for Organon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Postpartum hemorrhage is controlled via vacuum-induced uterine contraction devices.
|
Locked | Locked | 2020 | Locked | |
|
Small molecule therapeutics for inflammatory skin diseases are developed.
|
Locked | Locked | 2016 | Locked | |
|
Small molecule therapeutics for reproductive health are developed.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Organon
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Organon
Detailed financials for Organon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Organon Comparisons
Peer comparison for Organon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Organon
Organon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
Detailed competitors of Organon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Organon
Complete news archive for Organon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Organon
Organon is headquartered in Jersey City, United States. It is registered at Jersey City, New Jersey, United States.
Annual revenue of Organon is $6.4B as on Dec 31, 2024.
Organon is dedicated to advancing womens health through a diverse portfolio of over 70 medicines and devices. Focus areas include reproductive health, maternal conditions, and contraception, alongside biosimilars and established brands in cardiovascular, neurology, and dermatology sectors. Therapies are delivered to over 140 markets worldwide, addressing conditions unique to women or affecting them disproportionately. Solutions are developed to support women at all life stages, ensuring accessible healthcare options for patients and providers.
Organon's top competitors include Merck, Roivant Sciences and AbbVie.
Organon offers Women's Health Solutions, Biosimilars, and Established Brands.
Yes, Organon is publicly traded on NYSE under the ticker symbol OGN.
Organon has made 4 acquisitions, including Alydia Health, Dermavant, and Forendo Pharma.
Organon has 2 investors. Key investors include Merck, and Sun Pharma.
The ticker symbol of Organon is OGN on NYSE.